Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Lixte Biotechnology Holdings Inc

LIXT ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$4.05

▲ +0.00%

Market Cap $76.83M · Vol 36.05K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$76.83M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

44.19

Momentum

Beta

1.21

vs Market

52W High

$8.25

50.91% below

52W Low

$2.39

69.46% above

Volume

36.05K

Avg 68.27K

P/B

4.35

Price-to-book

ROE

N/A

Return on equity

Free Float

90.23%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Lixte Biotechnology Holdings Inc (LIXT) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LIXT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+12.50%

-29.81%

-19.64%

+32.79%

YTD

+3.05%

+3.85%

+63.31%

-81.92%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-6,009,520.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-86.60% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.35
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	18.97M

Technical Indicators

50-Day SMA	$5.78
200-Day SMA	$4.31
RSI (14)	44.19
Beta	1.21
52-Week High	$8.25
52-Week Low	$2.39

Volume Today	36.05K
Avg Daily Volume (30D)	68.27K
Relative Volume	0.53x
Volatility (10D)	122.90
Volatility (30D)	121.76
Free Float	90.23%

Analyst Consensus

N/A

Current Price $4.05

Mean Target N/A

52W Low$2.39 52W High$8.25

Current

Target

$2.39 $8.25

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SZV9C2

ISINUS5393193017

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.